## FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

Name and Address of Reporting Person*						2. Issuer Name <b>and</b> Ticker or Trading Symbol 5. Relationship of F											g Perso	n(s) to Issu	ıer	
					Athira Pharma, Inc. [ ATHA ]								(Che	(Check all applicable)  Director X 10% Owner						
(Last) (First) (Middle) 40 10TH AVENUE, FLOOR 7						3. Date of Earliest Transaction (Month/Day/Year) 09/18/2020									Officer (g below)	give title		Other ( below)		
(Street) NEW YORK NY 10014				4	4. If Amendment, Date of Original Filed (Month/Day/Year)								Line)	6. Individual or Joint/Group Filing (Check Applicable Line)     Form filed by One Reporting Person     X Form filed by More than One Reporting Person						
(City) (State) (Zip)																				
		Ţ	able I - No	n-Der	ivat	ive S	ecu	rities Ac	quired	, Dis	posed c	of, or E	Benefi	cially	Owned					
				2. Transaction Date (Month/Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr. 8)		4. Securities Acquired (A) o Disposed Of (D) (Instr. 3, 4 a						Form:	nership Direct Indirect str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
									Code	v	Amount	(A (I	A) or O)	Price	Transactio (Instr. 3 an	n(s) d 4)			(11150.4)	
Common Stock				09/1	09/18/2020				С		1,535,	,131 A		(1)	1,918,913				By RTW <sup>(2)</sup>	
Common Stock 09.				09/1	/18/2020				P		750,0	750,000 A		\$17	2,668,913				By RTW <sup>(2)</sup>	
			Table II -					ties Acq warrants							wned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Da if any (Month/Day/Y	Code (Instr.			Derivative E		Expiration	6. Date Exercisable Expiration Date (Month/Day/Year)		Securities Under		erlying	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported		10. Ownershi Form: Direct (D) or Indirec (I) (Instr. 4	Beneficial Ownership t (Instr. 4)	
				c	Code	de V		(D)	Date Exercisa		Expiration Date	Title		ount or nber of res		Transaction(s) (Instr. 4)				
Series B Convertible Preferred Stock	(1)	09/18/2020			С			1,535,131	(1)		(1)	Commo		35,131	(1)	0		I	By RTW <sup>(2)</sup>	
		Reporting Person* ENTS, LP	,			,							·			,		,		
(Last) (First) (Middle) 40 10TH AVENUE, FLOOR 7				e)																
(Street) NEW YORK NY			10014	10014																
(City)		(State)	(Zip)																	
	d Address of	Reporting Person* ICK																		
(Last) (First) C/O RTW INVESTMENT 40 10TH AVENUE, FLOO			(Middle	e)																
(Street)	)RK	NY	10014	1																

## **Explanation of Responses:**

(State)

(Zip)

(City)

1. Each share of Series B Convertible Preferred Stock is convertible into shares of Common Stock, on a one-for-one basis, has no expiration date and converted into shares of Common Stock upon the closing of the  $Is suer's\ initial\ public\ offering,\ which\ occurred\ on\ September\ 18,\ 2020.$ 

2. The securities reported herein may be deemed beneficially owned by each of: (i) RTW Investments, LP ("RTW"), which is deemed the beneficial owner of shares held by RTW Master Fund, Ltd., RTW Venture Fund Limited and RTW Innovation Master Fund, Ltd. (the "Funds"), which are investment funds managed by RTW, and (ii) Roderick Wong, M.D., who serves as the Managing Partner and Chief Investment Officer of RTW. Dr. Wong exercises voting and dispositive control over the securities held by RTW and is therefore deemed to be a beneficial owner of securities owned or controlled by RTW. Dr. Wong disclaims beneficial ownership of the reported securities held by the Funds, except to the extent of his pecuniary interest therein.

RTW Investments, LP By: /s/

Roderick Wong, Managing 09/22/2020

**Partner** 

Wong

Roderick Wong By: /s/ Roderick

09/22/2020

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.